David is Chief Medical Officer for the Institute for Clinical and Economic Review and an academic primary care physician at Beth Israel Deaconess Medical Center and Harvard Medical School. David has expertise in clinical epidemiology and evidence-based medicine and before coming to ICER, David was Vice President of Editorial at UpToDate. David led ICER’s reviews of emicizumab for patients with hemophilia A with inhibitors and of emicizumab and valoctocogene roxaparvovec for patients with hemophilia A without inhibitors.

David received a BA in chemistry from Yale University and his MD from the University of Rochester. He completed his residency in internal medicine at the University of Massachusetts Medical Center and then did a joint fellowship in general internal medicine and clinical computing at Beth Israel Hospital and Harvard Medical School. He received a Master of Science in health policy and management from the Harvard School of Public Health.